Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
2021 catalysts maintaining long-term momentum
Potential catalysts Selected examples
Major approvals
KesimptaⓇ (EU/JP)
RMS
EntrestoⓇ (US)
HFPEF
Achieved
Readout not supportive
Major
Alpelisib (BYL719)
PROS
Asciminib (ABL001)
CML
KymriahⓇ
FL
submissions¹
177 Lu-PSMA-617
Major readouts
Enabling submission 2021
Enabling submission 2022
Others
mCRPC
KymriahⓇ
aNHL 2L
Ligelizumab (QGE031)5
CSU
Iptacopan (LNP023)
Ph2 IgAN
Pivotal study
starts
Iptacopan (LNP023)
Ph3 IgAN
Ligelizumab (QGE031)
CINDU
Canakinumab (ACZ885)³
NSCLC 1L
CosentyxⓇ
HS
Iptacopan (LNP023) ✓
Ph2 PNH
Iptacopan (LNP023) ✓
Ph3 C3G
177Lu-PSMA-617
pre-taxane
1. First submission in any market. 2. Resubmitted to FDA. 3. Depending on timing of final readout submission may move to early 2022.
composite endpoint. The safety profile of EntrestoⓇ was confirmed. No submission planned. 5. Q4/2021-Q1/2022 potential COVID impact.
submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial.
Cosentyx® (US✓/JP/CN)
Pediatric psoriasis
JakaviⓇ
Acute and chronic GVHD
Leqvio® (US)²
Hyperlipidemia
EntrestoⓇ4
Post-AMI
No submission planned
Sabatolimab (MBG453)6
MDS
Iptacopan (LNP023)
Ph2 C3G
Iptacopan (LNP023)
Ph3 aHUS
177Lu-PSMA-617
MHSPC
BeovuⓇ
DME
Tislelizumab (VDT482)
2L esophageal cancer, NSCLC
KisqaliⓇ
Breast cancer (MONALEESA-2)
Ligelizumab (QGE031)
Food allergy
4. Numerical trends consistently favored EntrestoⓇ vs. active comparator but did not meet primary
6. Planned DMC readout for CR completed, study continues blinded to PFS readout, with
39 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation